Hospira and STADA's Biosimilar Epoetin Retacrit Receives Positive Opinion Recommending EU Approval
Hospira (Lake Forest, IL) has received a "positive opinion" recommending European Union (EU) approval for its biosimilar Retacrit (epoetin zeta), a treatment for anemia associated with chronic renal failure and chemotherapy-induced anemia.
Hospira (Lake Forest, IL) has received a "positive opinion" recommending European Union (EU) approval for its biosimilar Retacrit (epoetin zeta), a treatment for anemia associated with chronic renal failure and chemotherapy-induced anemia. Retacrit is a similar biologic, often referred to as a biosimilar or a biogeneric, to epoetin alfa.
The Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion, and the European Commission, which approves pharmaceuticals for use in Europe, usually follows CHMP recommendations. Hospira expects EU approval for Retacrit in late 2007. The company plans to launch the product, Hospira's first marketed similar biologic, in various EU countries beginning in early 2008.
In late 2006, Hospira, STADA Arzneimittel AG (Bad Vilbel, Germany), and BIOCEUTICALS Arzneimittel AG (Bad Vilbel, Germany) announced development, manufacturing, and distribution agreements for epoetin zeta. Under these agreements, Hospira obtained exclusive distribution rights for the product in countries including the US and much of Europe, with the exception of Germany, where Hospira and STADA will both market the product. The epoetin zeta project is being pursued through BIOCEUTICALS, a company spun out of STADA. STADA controlled the development process and conducted the approval process on behalf of BIOCEUTICALS and Hospira. Hospira has significantly invested in expanding to develop, manufacture, and market similar biologics.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
